Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Daily News

Most PCIs in US Now Done With Radial Access

Michael O'Riordan

July 10, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

L.A. McKeown

May 07, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

Yael L. Maxwell

March 24, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Industry News

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

January 21, 2025

Advertisement

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Most PCIs in US Now Done With Radial Access

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content